Jun. 22 at 7:49 PM
$GRI
GRI Bio's management team is heavily criticized by investors because their corporate strategy relies on aggressive equity dilution and destructive reverse stock splits that systematically wipe out retail shareholder value [^1.1.2]. Led by CEO Marc Hertz, the team has continually flooded the market with dilutive public offerings and executed a brutal 1-for-28 reverse split simply to maintain its Nasdaq listing requirements [^1.1.2]. This destruction of share price is aggravated by a severe pay-for-performance mismatch; proxy filings reveal the CEO receives over
$1 million in total annual compensation while the company struggles with only
$11 million in cash and admits to material weaknesses in its internal financial accounting controls [^1.1.2, 1.1.3].
